As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

The YOLT-203 in-vivo gene editing therapy was developed to treat patients living with primary hyperoxaluria type 1 (PH1), a condition caused by a genetic deficiency in the liver enzyme alanine ...